Reduced circulating oxytocin and high-molecular-weight adiponectin are risk factors for metabolic syndrome

Endocrine Journal

Volumn 63, Issue 7, 2016, Pages 655-662

  Yuan, Guoyue ^a   Qian, Weiyun ^b   Pan, Ruirong ^a   Jia, Jue ^a   Jiang, Dan ^a   Yang, Qichao ^a   Wang, Su ^a   Liu, Yuanxin ^a   Yu, Shuqin ^a   Hu, Hao ^a   Sun, Wenjun ^a   Ye, Jingjing ^a   Mao, Chaoming ^a   Zhuang, Ruo ^a   Zhou, Libin ^c  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

High molecular weight adiponectin; Metabolic syndrome; Oxytocin

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYTOCIN; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENDER; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; MIDDLE AGED; MOLECULAR WEIGHT;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR WEIGHT; OXYTOCIN; RISK FACTORS;

EID: 84979900693     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ16-0078     Document Type: Article

References (30)

1. Alberti K, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23: 469-480.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716.
3. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35: 2402-2411.
4. Cai D, Purkayastha S (2013) A new horizon: oxytocin as a novel therapeutic option for obesity and diabetes. Drug Discov Today Dis Mech 10: e63-e68.
5. Chaves VE, Tilelli CQ, Brito NA, Brito MN (2013) Role of oxytocin in energy metabolism. Peptides 45: 9-14.
6. Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden-Hanson T, et al. (2012) Peripheral oxytocin suppresses food intake and causes weight loss in dietinduced obese rats. Am J Physiol Endocrinol Metab 302: E134-E144.
7. Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, et al. (2011) Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One 6: e25565.
8. Zhang H, Wu C, Chen Q, Chen X, Xu Z, et al. (2013) Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One 8: e61477.
9. McGown C, Birerdinc A, Younossi ZM (2014) Adipose tissue as an endocrine organ. Clin Liver Dis 18: 41-58.
10. Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84-89.
11. Liu M, Liu F (2014) Regulation of adiponectin multimerization, signaling and function. Best Pract Res Clin Endocrinol Metab 28: 25-31.
12. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, et al. (2004) Adiponectin as a biomarker of the metabolic syndrome. Circ J 68: 975-981.
13. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, et al. (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29: 1357-1362.
14. Seino Y, Hirose H, Saito I, Itoh H (2007) High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 56: 1493-1499.
15. Qian W, Zhu T, Tang B, Yu S, Hu H, et al. (2014) Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J Clin Endocrinol Metab 99: 4683-4689.
16. Takayanagi Y, Kasahara Y, Onaka T, Takahashi N, Kawada T, et al. (2008) Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport 19: 951-955.
17. Camerino C (2009) Low sympathetic tone and obese phenotype in oxytocin-deficient mice. Obesity (Silver Spring) 17: 980-984.
18. Blevins JE, Graham JL, Morton GJ, Bales KL, Schwartz MW, et al. (2015) Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 308: R431-438.
19. Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, et al. (2011) Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY) 3: 1169-1177.
20. Petersson M, Lundeberg, Uvnäs-Moberg K (1997) Oxytocin decreases blood pressure in male but not in female spontaneously hypertensive rats. J Auton Nerv Syst 66: 15-18.
21. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162.
22. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, et al. (2006) Comparison of serum highmolecular-weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzymelinked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954-1960.
23. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, et al. (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54: 2712-2719.
24. Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K (2007) Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J 54: 431-435.
25. Szeto A, Rossetti MA, Mendez AJ, Noller CM, Herderick EE, et al. (2013) Oxytocin administration attenuates atherosclerosis and inflammation in Watanabe Heritable Hyperlipidemic rabbits. Psychoneuroendocrinology 38: 685-693.
26. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I (2008) Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 28: 1368-1374.
27. Yuan G, Chen X, Ma Q, Qiao J, Li R, et al. (2007) C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 194: 275-281.
28. Kaneko H, Anzai T, Nagai T, Anzai A, Takahashi T, et al. (2011) Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. Cardiovasc Res 91: 546-555.
29. Eckertova M, Ondrejcakova M, Krskova K, Zorad S, Jezova D (2001) Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis. Br J Pharmacol 162: 452-463.
30. Liu M, Liu F (2010) Transcriptional and post-translational regulation of adiponectin. Biochem J 425: 41-52.